Last C$0.57 CAD
Change Today +0.03 / 5.56%
Volume 500.0
IGX On Other Exchanges
Symbol
Exchange
OTC US
Venture
As of 3:17 PM 07/29/14 All times are local (Market data is delayed by at least 15 minutes).

intelgenx technologies corp (IGX) Snapshot

Open
C$0.57
Previous Close
C$0.54
Day High
C$0.57
Day Low
C$0.57
52 Week High
02/3/14 - C$1.33
52 Week Low
11/18/13 - C$0.46
Market Cap
36.0M
Average Volume 10 Days
13.1K
EPS TTM
--
Shares Outstanding
63.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INTELGENX TECHNOLOGIES CORP (IGX)

Related News

No related news articles were found.

intelgenx technologies corp (IGX) Related Businessweek News

No Related Businessweek News Found

intelgenx technologies corp (IGX) Details

IntelGenx Technologies Corp., a drug delivery company, develops novel oral immediate-release and controlled-release products for the pharmaceutical market. Its product portfolio comprises INT0001/2004 for coronary heart failure and hypertension; INT0004/2006, an antidepressant; INT0007/2006 for the treatment of erectile dysfunction; INT0008/2007 for the treatment of migraine; INT0024/2010 for idiopathic pulmonary fibrosis; INT0027/2011 for opioid dependence; INT0028/2011 for cancer pain; INT0030/2011 for animal health; and INT0036/2012 for central nervous system disorders, as well as INT0037/2013 and INT0039/2013. The company develops its products based on three delivery platform technologies, which consist of the Multilayer Tablet technology that allows for the development of oral controlled-release products; the Oral Film technology, which allows for the delivery of pharmaceuticals to the oral cavity; and the Mucoadhesive Tablet technology for the controlled release of active substances to the oral mucosa. It also provides product development services for the pharmaceutical industry, including the branded and generic pharmaceutical markets. The company has a strategic alliance with LTS Lohmann Therapie-Systeme AG to manufacture pharmaceutical products using VersaFilm drug delivery technology; and a strategic manufacturing partnership with Pillar5 Pharma Inc. IntelGenx Technologies Corp. also has a co-development and commercialization agreement with RedHill Biopharma Ltd. for the co-development and commercialization of INT0008/2007. IntelGenx Technologies Corp. was founded in 2003 and is based in Ville Saint Laurent, Canada.

12 Employees
Last Reported Date: 03/11/14
Founded in 2003

intelgenx technologies corp (IGX) Top Compensated Officers

Chairman of the Board, Interim Chief Executiv...
Total Annual Compensation: $261.4K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $230.5K
Compensation as of Fiscal Year 2013.

intelgenx technologies corp (IGX) Key Developments

IntelGenx Technologies Corp. - Special Call

To provide a business update and discussion regarding the company's recent management changes

IntelGenx Technologies Corp. Announces Management Changes

IntelGenx Technologies Corp. announced that the board of directors has accepted, with immediate effect, the resignation of Dr. Rajiv Khosla as President and Chief Executive Officer of IntelGenx and as a member of the board. Effective immediately, the board has appointed Dr. Horst G. Zerbe to serve as IntelGenx' interim President and CEO until a successor is found. A Search Committee has been formed by the Board to begin the search, selection and appointment of a new President and CEO. Dr. Zerbe is the Chairman of the Board, founder, and former President and CEO of the company. He retired from the positions of President and CEO effective December 31, 2013.

IntelGenx and Redhill Biopharma Reports Positive Bioavailability Study Results in Support of Planned European Marketing Application

IntelGenx Corp. reported, together with RedHill Biopharma Ltd. positive results from a comparative bioavailability study with their anti-migraine VersaFilm(TM) product, an oral thin film formulation of rizatriptan for acute migraines. The study compared the anti-migraine VersaFilm(TM) product to the European reference drug Maxalt(R) lingua, marketed in Germany by MSD SHARP & DOHME GMBH, to support the planned submission of a European Marketing Authorization Application (MAA) for the anti-migraine VersaFilm(TM) product during the third quarter of 2014. The results of the study are subject to final quality assurance and an independent study report by the Canadian clinical research organization (CRO) that conducted the study. The final independent report from the CRO is expected in the coming weeks. The single-dose, crossover, comparative bioavailability study conducted in Canada followed a positive scientific advice meeting with the German Federal Institute for Drugs and Medical Devices (BfArM) previously announced by RedHill in November 2013. The study, which included 26 healthy volunteers, established the bioequivalence of the anti-migraine VersaFilm(TM) product and the European reference drug, Maxalt(R) lingua. In light of the positive results from the bioavailability study and data from prior clinical studies conducted with the anti-migraine VersaFilm(TM) product, and subject to various regulatory requirements, IntelGenx and RedHill plan to submit a European MAA during the third quarter of 2014. IntelGenx and RedHill previously conducted a successful bioavailability study which demonstrated the required U.S. Food and Drug Administration (FDA) criteria for therapeutic bioequivalence between the anti-migraine VersaFilm(TM) soluble oral thin film product and the U.S. reference drug, Maxalt-MLT(R). Following the successful bioequivalence study, IntelGenx and RedHill announced in 2013 the submission to the FDA and acceptance for review of a New Drug Application (NDA) seeking marketing approval of the anti-migraine VersaFilm(TM) product. Following a Complete Response Letter received from the FDA in February 2014, which raised questions primarily related to Chemistry, Manufacturing and Controls (CMC), IntelGenx and RedHill recently reported that they believe that FDA approval of the anti-migraine VersaFilm(TM) product NDA is subject to the satisfactory resolution of the remaining CMC questions, as well as securing a compliant source of the raw material. Accordingly, the companies continue to work with the FDA in order to address and resolve all remaining CMC questions and to secure a compliant source of the raw material.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IGX:CN C$0.57 CAD +0.03

IGX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioDelivery Sciences International Inc $13.05 USD +0.50
View Industry Companies
 

Industry Analysis

IGX

Industry Average

Valuation IGX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 30.6x
Price/Book 5.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 26.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INTELGENX TECHNOLOGIES CORP, please visit www.intelgenx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.